ACXP News and Press, Acurx Pharmaceuticals Inc. From 08/15/22

Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q2 GAAP EPS of -$0.26. The company ended the second quarter on Jun 30, 2022, with cash totaling $9.1M compared to $13.1M as of Dec. 31, 2021. For further details see: Acurx Pharmaceuticals GAAP EPS of -$0.26 ...

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Aug. 15, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical s...

Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" ...

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America PR Newswire New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from ...

Clinical-stage biopharmaceutical company, Acurx Pharmaceuticals ( NASDAQ: ACXP ) entered agreement with a single healthcare-focused U.S. institutional investor and certain executives of the company for the purchase and sale of an aggregate of 1.29M shares (...

Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering PR Newswire STATEN ISLAND, N.Y. , July 25, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical compa...

Seres' $100 million share placement with strategic partners, including Nestle, helps stabilize the share price. The C. difficile market - how big is it? Who can compete with the Seres/Nestle (Aimmune Therapeutics) global rollout for C. difficile recurrence? Seres has had two share...

SER-109 has shown an excellent efficacy and safety profile but is entering a small and crowded market. SER-287 and SER-301 have shown no efficacy. SER-401 did not show efficacy in metastatic melanoma patients. SER-155 has not yet achieved proof of concept but is the most promi...

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2022 Earnings Conference Call May 11, 2022 8:30 A.M. ET Company Participants Rob Shawah - Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Chad Yahn - Maxim Group Joanne Lee - Maxim Group Presentation...

Acurx Pharmaceuticals press release (NASDAQ:ACXP): Q1 GAAP EPS of -$0.26 beats by $0.07. Cash balance of $1.08M  as of March31, 2022 For further details see: Acurx Pharmaceuticals GAAP EPS of -$0.26 beats by $0.07